'In a Year, We'll Know': Isis' Kynamro Faces Juxtapid Pill

Timing of the launch, how to identify new patients and the retry for approval in Europe  along with, of course, price  became topics of talk in the aftermath of Kynamro's approval Tuesday by the FDA for homozygous familial hypercholesterolemia (HoFH).